Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025
Verrica Pharmaceuticals (VRCA) reported significant growth in YCANTH® dispensed applicator units for Q1 2025, reaching 10,102 units - a 16.7% sequential increase from Q4 2024's 8,654 units.
The company attributes this growth to their recent commercial restructuring and normalized distribution inventory levels. With stabilized channel inventory, the dispensed units are expected to more closely track demand and gross revenue going forward.
The management highlighted that strong market access, normalized inventory levels, and a focused commercial team building relationships within dermatology and pediatric communities position YCANTH® for sustainable revenue growth. The company aims to establish YCANTH® as the standard treatment for molluscum contagiosum.
Verrica Pharmaceuticals (VRCA) ha riportato una crescita significativa nelle unità di applicatore dispensato di YCANTH® per il primo trimestre del 2025, raggiungendo 10.102 unità - un aumento sequenziale del 16,7% rispetto alle 8.654 unità del quarto trimestre del 2024.
L'azienda attribuisce questa crescita alla recente ristrutturazione commerciale e ai livelli di inventario di distribuzione normalizzati. Con l'inventario del canale stabilizzato, si prevede che le unità dispensate seguano più da vicino la domanda e le entrate lorde in futuro.
La direzione ha sottolineato che un forte accesso al mercato, livelli di inventario normalizzati e un team commerciale focalizzato nel costruire relazioni all'interno delle comunità dermatologiche e pediatriche pongono YCANTH® in una posizione favorevole per una crescita sostenibile delle entrate. L'azienda mira a stabilire YCANTH® come trattamento standard per il mollusco contagioso.
Verrica Pharmaceuticals (VRCA) reportó un crecimiento significativo en las unidades de aplicador dispensado de YCANTH® para el primer trimestre de 2025, alcanzando 10,102 unidades - un aumento secuencial del 16.7% respecto a las 8,654 unidades del cuarto trimestre de 2024.
La compañía atribuye este crecimiento a su reciente reestructuración comercial y a los niveles de inventario de distribución normalizados. Con el inventario del canal estabilizado, se espera que las unidades dispensadas sigan más de cerca la demanda y los ingresos brutos en el futuro.
La dirección destacó que un fuerte acceso al mercado, niveles de inventario normalizados y un equipo comercial enfocado en construir relaciones dentro de las comunidades dermatológicas y pediátricas posicionan a YCANTH® para un crecimiento sostenible de los ingresos. La empresa tiene como objetivo establecer YCANTH® como el tratamiento estándar para el molusco contagioso.
Verrica Pharmaceuticals (VRCA)는 2025년 1분기 YCANTH® 분배기 유닛에서 10,102 유닛에 도달하며 16.7%의 순차적 증가를 보고했습니다. 이는 2024년 4분기의 8,654 유닛에 비해 증가한 수치입니다.
회사는 이 성장을 최근의 상업적 구조 조정과 정상화된 유통 재고 수준에 기인한다고 설명했습니다. 안정화된 채널 재고로 인해 앞으로 분배된 유닛은 수요와 총 수익을 더 밀접하게 추적할 것으로 예상됩니다.
경영진은 강력한 시장 접근, 정상화된 재고 수준, 그리고 피부과 및 소아 커뮤니티 내에서 관계를 구축하는 데 집중하는 상업 팀이 YCANTH®의 지속 가능한 수익 성장에 기여할 것이라고 강조했습니다. 회사는 YCANTH®를 연체동물 전염증에 대한 표준 치료제로 확립할 계획입니다.
Verrica Pharmaceuticals (VRCA) a signalé une croissance significative des unités d'applicateur dispensé de YCANTH® pour le premier trimestre de 2025, atteignant 10 102 unités - une augmentation séquentielle de 16,7% par rapport aux 8 654 unités du quatrième trimestre 2024.
L'entreprise attribue cette croissance à sa récente restructuration commerciale et aux niveaux normalisés des stocks de distribution. Avec un inventaire de canal stabilisé, il est prévu que les unités dispensées suivent de plus près la demande et les revenus bruts à l'avenir.
La direction a souligné qu'un accès au marché solide, des niveaux de stocks normalisés et une équipe commerciale concentrée sur l'établissement de relations au sein des communautés dermatologiques et pédiatriques positionnent YCANTH® pour une croissance durable des revenus. L'entreprise vise à établir YCANTH® comme le traitement standard pour le molluscum contagiosum.
Verrica Pharmaceuticals (VRCA) berichtete von einem signifikanten Wachstum der ausgegebenen Applikatoreinheiten von YCANTH® für das erste Quartal 2025, mit 10.102 Einheiten - ein sequentieller Anstieg von 16,7% im Vergleich zu den 8.654 Einheiten im vierten Quartal 2024.
Das Unternehmen führt dieses Wachstum auf die kürzliche kommerzielle Umstrukturierung und normalisierte Verteilungsbestände zurück. Mit stabilisierten Kanalbeständen wird erwartet, dass die ausgegebenen Einheiten künftig enger an der Nachfrage und den Bruttoeinnahmen ausgerichtet sind.
Das Management hob hervor, dass ein starker Marktzugang, normalisierte Bestandsniveaus und ein fokussiertes Vertriebsteam, das Beziehungen innerhalb der Dermatologie- und Pädiatrie-Communities aufbaut, YCANTH® für ein nachhaltiges Umsatzwachstum positioniert. Das Unternehmen hat sich zum Ziel gesetzt, YCANTH® als Standardbehandlung für Molluscum contagiosum zu etablieren.
- First-time achievement of over 10,000 quarterly dispensed units (10,102)
- 16.7% sequential quarterly growth in dispensed units
- Normalized distribution inventory levels enabling better demand tracking
- Strong market access established for YCANTH
- None.
Insights
Verrica Pharmaceuticals' Q1 2025 report reveals significant operational progress with YCANTH®, their treatment for molluscum contagiosum (a common viral skin infection). The 16.7% sequential growth in dispensed applicator units—reaching 10,102 units compared to Q4 2024's 8,654—represents an important inflection point for the company.
What makes this quarter particularly noteworthy is the normalization of distribution inventory levels. This indicates that dispensed units now reflect actual market demand rather than inventory loading, creating a more reliable connection between units and revenue generation. For a microcap pharmaceutical company (
The company's commercial restructuring appears to be yielding tangible results. With their three-pronged foundation now in place—strong market access, normalized inventory, and a focused commercial team—Verrica has created the infrastructure needed for sustainable growth. This quarter's performance suggests YCANTH is gaining traction among prescribers in both dermatology and pediatric settings.
While specific revenue figures weren't disclosed, the unit volume increase combined with management's confident outlook indicates positive momentum. For investors, this represents a meaningful step toward establishing commercial viability for YCANTH as the company works to position it as the standard of care for molluscum contagiosum treatment.
– Company generated quarterly sequential growth with Q1 YCANTH® dispensed applicator units rising above 10,000 for the first time in a quarter –
– As YCANTH distributor inventory levels have normalized, Company expects that dispensed applicator units will now more closely track demand and gross revenue –
WEST CHESTER, Pa., April 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Company experienced strong demand-led growth for YCANTH® in the first quarter of 2025, with the number of dispensed applicator units increasing to 10,102 in the first quarter. This first quarter growth represents a sequential increase of
“We believe the strong performance we experienced for YCANTH in first quarter of 2025 reflects the positive impact from our recent commercial restructuring,” said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica. “Importantly, our YCANTH distribution inventory has normalized. The sequential growth in the first quarter represents increasing demand for YCANTH by prescribers, which we believe will drive revenue.” Dr. Rieger emphasized, “ With strong market access now in place, normalized channel inventory levels, and a more focused commercial team that continues to build solid relationships within the dermatology and pediatric communities, I believe we are now positioned for sustainable revenue growth in 2025 and beyond as we seek to establish YCANTH as the standard of care for the treatment of molluscum contagiosum.”
Company to Participate in Fireside Chat at 24th Annual Needham Virtual Healthcare Conference
As previously announced, Dr. Rieger will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference.
Event details:
Date: Tuesday, April 8, 2025
Time: 1:30 pm ET
Location: Virtual
Participants may access a live webcast of the event by clicking the link here.
The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com. A replay of the webcast will be posted shortly after the presentation and will be available for 90 days following the event.
About YCANTH® (VP-102)
YCANTH® is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin delivered via a single-use applicator that allows for precise topical dosing and targeted administration for the treatment of molluscum. YCANTH® is the first and only commercially available product approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum — a common, highly contagious skin disease that affects an estimated six million people in the United States, primarily children. Approval of YCANTH® was based upon the positive results from two Phase 3 clinical trials in approximately 500 patients which demonstrated that YCANTH® was a safe and effective therapeutic for the treatment of molluscum. Approximately 225 million lives are eligible to receive YCANTH® covered by insurance. YCANTH® is available to all patients with and without insurance coverage for
About Verrica Pharmaceuticals Inc.
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s product YCANTH® (VP-102) (cantharidin), is the first and only commercially available treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (formerly LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com.
About Dispensed Applicator Units
Dispensed applicator units represent applicators (a) shipped to healthcare professionals from Verrica’s contracted pharmacy partners for fulfillment, (b) sold by Verrica’s distribution partners to independent and regional pharmacies , and (c) sold to physician offices, hospitals and other clinics on a buy and bill basis.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe,” “expect,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Verrica’s current beliefs and expectations. These forward-looking statements include statements about Verrica’s ability to sustain revenue growth, the commercialization of YCANTH and the clinical development and benefits of Verrica’s product candidates, including YCANTH (VP-102) and VP-315. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include risks and uncertainties related to market conditions, satisfaction of customary closing conditions related to the proposed public offering and other risks and uncertainties that are described in Verrica’s Annual Report on Form 10-K for the year ended December 31, 2024 and other filings Verrica makes with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Verrica as of the date of this release, and Verrica assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
FOR MORE INFORMATION, PLEASE CONTACT:
Investors:
John J Kirby
Interim Chief Financial Officer
jkirby@verrica.com
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
FAQ
How many YCANTH applicator units did Verrica (VRCA) dispense in Q1 2025?
What was the sequential growth rate for VRCA's YCANTH dispensed units in Q1 2025?
What factors contributed to YCANTH's growth in Q1 2025?
What is VRCA's strategic goal for YCANTH in the molluscum contagiosum market?
